Fabrinet vs Stryker Corporation — how do they compare? Fabrinet trades at $460 (market cap $17.44B), while Stryker Corporation trades at $320 (market cap $121.31B). The key difference: Stryker Corporation is far larger — about 7× Fabrinet's market cap, and Stryker Corporation pays a 1.11% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | SYK | |
|---|---|---|
Market Cap | $17.44B | $121.31B |
Sector | Technology | Technology |
52-Week High | $746.47 | $403.53 |
52-Week Low | $277.04 | $282.58 |
Enterprise Value | $16.50B | $133.07B |
Dividend Yield | — | 1.11% |
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $460.16, down 4.69% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.72 exceeding expectations, driven by 39% YoY revenue growth in optical communications. Analyst consensus remains strongly bullish with 18 buy ratings and a $733 price target, though technical indicators show selling pressure with support at $448.
The outlook remains positive given Fabrinet's strategic position in AI infrastructure and optical communications, with projected revenue growth to $4.2B in 2026. Key risks include premium valuation multiples and supply chain constraints, but the debt-free balance sheet and expanding margins support long-term growth potential in the AI-driven data center market.
Stryker (SYK) trades at $329.38, up 5.84% in the last session, yet technical indicators signal a bearish trend. The company reported a Q1 2026 earnings miss due to a temporary cyber disruption but maintained full-year guidance, with strong profitability margins and robust cash flow. Recent news highlights expansion of its Mako robotics platform, reinforcing its innovation-led growth strategy in the medical technology sector.
The investment outlook is positive based on strong fundamentals and analyst consensus, but near-term risks include competitive pressures and execution challenges. With a consensus price target of $388.44 representing ~18% upside, the stock offers value for long-term investors, though volatility may persist until Q2 earnings clarify the post-disruption recovery.
Trailing returns across standard periods
Latest headlines on both assets
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →